Chief Executive Officer
Lymfactin® for lymphedema
Lymphedema means chronic, progressive swelling of affected tissues. Approximately 20% of breast cancer patients who undergo axillary lymph node dissection get secondary lymphedema, a disabling and disfiguring condition that severely affects quality of life. There is no cure.
Over 200,000 patients in the USA and Europe are estimated to live with breast-cancer associated lymphedema, with an estimated 30,000 new patients developing the complication each year. Secondary lymphedema is currently treated e.g. with compression garments, special massage, and exercises. While these therapies may relief the symptoms they do not cure the condition, which is caused by damage to the lymph system.
Herantis’ Lymfactin® aims at recovering the damaged lymph system by reconstituting lymphatic vasculature. Preclinical pharmacology studies in lymphedema models have confirmed the effects of Lymfactin® on growth of new functional lymphatic vessels and functional improvement of lymphatic flow.
Herantis has launched a phase I clinical study to be conducted at 3 European clinical sites, in women with breat cancer associated secondary lymphedema. The first site opened for patient recruitment in May 2016 is Helsinki University Central Hospital. While the primary endpoint of the study is to assess the safety and tolerability of Lymfactin® the study will also assess the preliminary efficacy of the treatment. The study intends to recruit at most 18 patients and recruitment is expected to be completed in 2017.